Wnt signaling as potential therapeutic target in lung cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• Han F, He J, Li F, et al. Emerging roles of microRNAs in EGFR-targeted therapies for lung cancer. Biomed Res Int. 2015;2015:672759.
   PubMed Web of Science ®Google Scholar
• Chuang JC, Neal JW, Niu XM, et al. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: current data and future prospects. Lung Cancer. 2015;90:1–7.
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Campo MJ, Dahlberg SE, et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015;10:S1–63.
   PubMed Web of Science ®Google Scholar
• Delaney C, Frank S, Huang RS. Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond. Chin J Cancer. 2015;34:149–160.
   PubMed Web of Science ®Google Scholar
• Takebe N, Miele L, Harris PJ, et al. Targeting notch, hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12:445–464.
   PubMed Web of Science ®Google Scholar
• Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13:513–532.
   PubMed Web of Science ®Google Scholar
• Le PN, McDermott JD, Jimeno A. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther. 2015;146:1–11.
   PubMed Web of Science ®Google Scholar
• Song L, Li Y, He B, et al. Development of small molecules targeting the Wnt signaling pathway in cancer stem cells for the treatment of colorectal cancer. Clin Colorectal Cancer. 2015;14:133–145.
   PubMed Web of Science ®Google Scholar
• Madan B, Virshup DM. Targeting Wnts at the source – new mechanisms, new biomarkers, new drugs. Mol Cancer Ther. 2015;14:1087–1094.
   PubMed Web of Science ®Google Scholar
• Li C, Bellusci S, Borok Z, et al. Non-canonical WNT signalling in the lung. J Biochem. 2015;158:355–365.
   Web of Science ®Google Scholar
• Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469–480.
   PubMed Web of Science ®Google Scholar
• Coscio A, Chang DW, Roth JA, et al. Genetic variants of the Wnt signaling pathway as predictors of recurrence and survival in early-stage non-small cell lung cancer patients. Carcinogenesis. 2014;35:1284–1291.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011;22:2616–2624.
   PubMed Web of Science ®Google Scholar
• Akiri G, Cherian MM, Vijayakumar S, et al. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene. 2009;28:2163–2172.
   PubMed Web of Science ®Google Scholar
• Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27–56.
   PubMed Web of Science ®Google Scholar
• Bartis D, Csongei V, Weich A, et al. Down-regulation of canonical and up-regulation of non-canonical Wnt signalling in the carcinogenic process of squamous cell lung carcinoma. Plos One. 2013;8:e57393.
   PubMed Web of Science ®Google Scholar
• Stewart DJ Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 2014;106:djt356.
   PubMedGoogle Scholar
• Nakata A, Yoshida R, Yamaguchi R, et al. Elevated beta-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Sci Rep. 2015;5:13076.
   PubMed Web of Science ®Google Scholar
• Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lou Y, Zheng X, et al. Wnt blockers inhibit the proliferation of lung cancer stem cells. Drug Des Devel Ther. 2015;9:2399–2407.
   PubMed Web of Science ®Google Scholar
• Wang XY, Penalva LO, Yuan H, et al. Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer. 2010;9:221.
   Web of Science ®Google Scholar
• Xu X, Sun PL, Li JZ, et al. Aberrant Wnt1/beta-catenin expression is an independent poor prognostic marker of non-small cell lung cancer after surgery. J Thorac Oncol. 2011;6:716–724.
   PubMed Web of Science ®Google Scholar
• Nakashima N, Huang CL, Liu D, et al. Intratumoral Wnt1 expression affects survivin gene expression in non-small cell lung cancer. Int J Oncol. 2010;37:687–694.
   PubMed Web of Science ®Google Scholar
• You L, He B, Xu Z, et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene. 2004;23:6170–6174.
   PubMed Web of Science ®Google Scholar
• Nakashima N, Liu D, Huang CL, et al. Wnt3 gene expression promotes tumor progression in non-small cell lung cancer. Lung Cancer. 2012;76:228–234.
   PubMed Web of Science ®Google Scholar
• Malanchi I, Santamaria-Martinez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012;481:85–89.
   PubMed Web of Science ®Google Scholar
• Huang C, Ma R, Xu Y, et al. Wnt2 promotes non-small cell lung cancer progression by activating WNT/beta-catenin pathway. Am J Cancer Res. 2015;5:1032–1046.
   PubMed Web of Science ®Google Scholar
• Bravo DT, Yang YL, Kuchenbecker K, et al. Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer. BMC cancer. 2013;13:316.
   Google Scholar
• Winn RA, Van Scoyk M, Hammond M, et al. Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem. 2006;281:26943–26950.
   PubMed Web of Science ®Google Scholar
• Kim TH, Moon JY, Kim SH, et al. Clinical significance of aberrant Wnt7a promoter methylation in human non-small cell lung cancer in Koreans. J Korean Med Sci. 2015;30:155–161.
   PubMed Web of Science ®Google Scholar
• He B, You L, Uematsu K, et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia. 2004;6:7–14.
   PubMed Web of Science ®Google Scholar
• Nakashima T, Liu D, Nakano J, et al. Wnt1 overexpression associated with tumor proliferation and a poor prognosis in non-small cell lung cancer patients. Oncol Rep. 2008;19:203–209.
   PubMed Web of Science ®Google Scholar
• Guo Q, Shen S, Liao M, et al. NGX6 inhibits cell invasion and adhesion through suppression of Wnt/beta-catenin signal pathway in colon cancer. Acta Biochim Biophys Sin (Shanghai). 2010;42:450–456.
   PubMed Web of Science ®Google Scholar
• Winn RA, Marek L, Han SY, et al. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem. 2005;280:19625–19634.
   PubMed Web of Science ®Google Scholar
• Wang HQ, Xu ML, Ma J, et al. Frizzled-8 as a putative therapeutic target in human lung cancer. Biochem Biophys Res Commun. 2012;417:62–66.
   PubMed Web of Science ®Google Scholar
• Li C, Chen H, Hu L, et al. Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol Biol. 2008;9:11.
   PubMed Web of Science ®Google Scholar
• Lu C, Wang X, Zhu H, et al. Over-expression of ROR2 and Wnt5a cooperatively correlates with unfavorable prognosis in patients with non-small cell lung cancer. Oncotarget. 2015;6:24912–24921.
   Web of Science ®Google Scholar
• Zhao H, Zhao Y, Jiang G, et al. Dishevelled-3 activates p65 to upregulate p120-catenin transcription via a p38-dependent pathway in non-small cell lung cancer. Mol Carcinog. 2015;54(Suppl 1):E112–21.
   Google Scholar
• Kren L, Hermanova M, Goncharuk VN, et al. Downregulation of plasma membrane expression/cytoplasmic accumulation of beta-catenin predicts shortened survival in non-small cell lung cancer. A clinicopathologic study of 100 cases. Cesk Patol. 2003;39:17–20.
   PubMedGoogle Scholar
• Xu C, Xie D, Yu SC, et al. beta-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res. 2013;73:3181–3189.
   PubMed Web of Science ®Google Scholar
• Pronobis MI, Rusan NM, Peifer M. A novel GSK3-regulated APC: axin interaction regulates Wnt signaling by driving a catalytic cycle of efficient betacatenin destruction. Elife. 2015;4:e08022.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li H, Hou S, et al. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. Plos One. 2013;8:e65309.
   PubMed Web of Science ®Google Scholar
• Tang M, Torres-Lanzas J, Lopez-Rios F, et al. Wnt signaling promoter hypermethylation distinguishes lung primary adenocarcinomas from colorectal metastasis to the lung. Int J Cancer J Int Du Cancer. 2006;119:2603–2606.
   PubMed Web of Science ®Google Scholar
• Xie J, Zhang Y, Hu X, et al. Norcantharidin inhibits Wnt signal pathway via promoter demethylation of WIF-1 in human non-small cell lung cancer. Med Oncol. 2015;32:592.
   Google Scholar
• Xu H, Wu J, Chen B, et al. Serum dickkopf-1 (DKK1) is significantly lower in patients with lung cancer but is rapidly normalized after treatment. Am J Transl Res. 2014;6:850–856.
   PubMed Web of Science ®Google Scholar
• Yue W, Sun Q, Dacic S, et al. Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis. 2008;29:84–92.
   PubMed Web of Science ®Google Scholar
• Xie C, Jiang G, Fan C, et al. ARMC8alpha promotes proliferation and invasion of non-small cell lung cancer cells by activating the canonical Wnt signaling pathway. Tumour Biology: J Int Soc Oncodevelopmental Biol Med. 2014;35:8903–8911.
   PubMed Web of Science ®Google Scholar
• Yang X, Li L, Huang Q, et al. Wnt signaling through Snail1 and Zeb1 regulates bone metastasis in lung cancer. Am J Cancer Res. 2015;5:748–755.
   PubMed Web of Science ®Google Scholar
• Endo M, Nishita M, Fujii M, et al. Insight into the role of Wnt5a-induced signaling in normal and cancer cells. Int Rev Cell Mol Biol. 2015;314:117–148.
   PubMed Web of Science ®Google Scholar
• Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. Plos Biology. 2006;4:e115.
   PubMed Web of Science ®Google Scholar
• Shabani M, Naseri J, Shokri F. Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy. Expert Opin Ther Targets. 2015;19:941–955.
   PubMed Web of Science ®Google Scholar
• Debebe Z, Rathmell WK. Ror2 as a therapeutic target in cancer. Pharmacol Ther. 2015;150:143–148.
   PubMed Web of Science ®Google Scholar
• Henry C, Quadir A, Hawkins NJ, et al. Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both beta-catenin dependent and independent Wnt signalling. J Cancer Res Clin Oncol. 2015;141:243–254.
   PubMed Web of Science ®Google Scholar
• Lesko AC, Goss KH, Prosperi JR. Exploiting APC function as a novel cancer therapy. Curr Drug Targets. 2014;15:90–102.
   PubMed Web of Science ®Google Scholar
• He W, He S, Wang Z, et al. Astrocyte elevated gene-1(AEG-1) induces epithelial-mesenchymal transition in lung cancer through activating Wnt/beta-catenin signaling. BMC Cancer. 2015;15:107.
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu L, Cai J, et al. DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/beta-catenin signaling. Biochem Biophys Res Commun. 2014;450:899–905.
   PubMed Web of Science ®Google Scholar
• Okamoto J, Hirata T, Chen Z, et al. EMX2 is epigenetically silenced and suppresses growth in human lung cancer. Oncogene. 2010;29:5969–5975.
   PubMed Web of Science ®Google Scholar
• Chen X, Meng J, Yue W, et al. Fibulin-3 suppresses Wnt/beta-catenin signaling and lung cancer invasion. Carcinogenesis. 2014;35:1707–1716.
   PubMed Web of Science ®Google Scholar
• Wang R, Huang J, Feng B, et al. Identification of ING4 (inhibitor of growth 4) as a modulator of docetaxel sensitivity in human lung adenocarcinoma. Mol Med. 2012;18:874–886.
   PubMed Web of Science ®Google Scholar
• Chen B, Ma X, Liu S, et al. Inhibition of lung cancer cells growth, motility and induction of apoptosis by Klotho, a novel secreted Wnt antagonist, in a dose-dependent manner. Cancer Biol Ther. 2012;13:1221–1228.
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang X. Klotho: a novel biomarker for cancer. J Cancer Res Clin Oncol. 2015;141:961–969.
   PubMed Web of Science ®Google Scholar
• Douchi D, Ohtsuka H, Ariake K, et al. Silencing of LRRFIP1 reverses the epithelial-mesenchymal transition via inhibition of the Wnt/beta-catenin signaling pathway. Cancer Letters. 2015;365:132–140.
   PubMed Web of Science ®Google Scholar
• Bartling B, Rehbein G, Simm A, et al. Porcupine expression is associated with the expression of S100P and other cancer-related molecules in non-small cell lung carcinoma. Int J Oncol. 2010;36:1015–1021.
   PubMed Web of Science ®Google Scholar
• Zhou SY, Xu ML, Wang SQ, et al. Overexpression of Pygopus-2 is required for canonical Wnt activation in human lung cancer. Oncol Lett. 2014;7:233–238.
   PubMed Web of Science ®Google Scholar
• Jian SF, Hsiao CC, Chen SY, et al. Utilization of liquid chromatography mass spectrometry analyses to identify LKB1-APC interaction in modulating Wnt/beta-catenin pathway of lung cancer cells. Mol Cancer Res: MCR. 2014;12:622–635.
   PubMed Web of Science ®Google Scholar
• Gao Y, Song C, Hui L, et al. Overexpression of RNF146 in non-small cell lung cancer enhances proliferation and invasion of tumors through the Wnt/beta-catenin signaling pathway. Plos One. 2014;9:e85377.
   Google Scholar
• Ueda M, Gemmill RM, West J, et al. Mutations of the beta- and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer. 2001;85:64–68.
   PubMed Web of Science ®Google Scholar
• Nakatani Y, Masudo K, Miyagi Y, et al. Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules. Mod Pathology: Off J United States Can Acad Pathology. 2002;15:617–624.
   PubMed Web of Science ®Google Scholar
• Sunaga N, Kohno T, Kolligs FT, et al. Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer. 2001;30:316–321.
   PubMed Web of Science ®Google Scholar
• Garnis C, Campbell J, Davies JJ, et al. Involvement of multiple developmental genes on chromosome 1p in lung tumorigenesis. Hum Mol Genet. 2005;14:475–482.
   PubMed Web of Science ®Google Scholar
• Lee SM, Park JY, Kim DS. Wif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation. Mol Cells. 2013;36:69–73.
   PubMed Web of Science ®Google Scholar
• Licchesi JD, Westra WH, Hooker CM, et al. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis. 2008;29:895–904.
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang Y, Duan J, et al. DNA methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. J Exp Clin Cancer Research: CR. 2012;31:80.
   PubMed Web of Science ®Google Scholar
• Shu J, Jelinek J, Chang H, et al. Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res. 2006;66:5077–5084.
   PubMed Web of Science ®Google Scholar
• Fukui T, Kondo M, Ito G, et al. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene. 2005;24:6323–6327.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Wada H, Yoshino M, et al. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. Ann Surg Oncol. 2010;17:878–888.
   PubMed Web of Science ®Google Scholar
• Templeton AK, Miyamoto S, Babu A, et al. Cancer stem cells: progress and challenges in lung cancer. Stem Cell Investig. 2014;2014:e9.
   Google Scholar
• Islam F, Gopalan V, Smith RA, et al. Translational potential of cancer stem cells: a review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment. Exp Cell Res. 2015;335:135–147.
   PubMed Web of Science ®Google Scholar
• Okudela K, Woo T, Mitsui H, et al. Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and beta-catenin, in primary lung adenocarcinoma – their prognostic significance. Pathol Int. 2012;62:792–801.
   PubMed Web of Science ®Google Scholar
• Alamgeer M, Peacock CD, Matsui W, et al. Cancer stem cells in lung cancer: evidence and controversies. Respirology. 2013;18:757–764.
   PubMed Web of Science ®Google Scholar
• Pine SR, Marshall B, Varticovski L. Lung cancer stem cells. Dis Markers. 2008;24:257–266.
   PubMed Web of Science ®Google Scholar
• Qu H, Li R, Liu Z, et al. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol. 2013;6:2644–2650.
   PubMed Web of Science ®Google Scholar
• Tan Y, Chen B, Xu W, et al. Clinicopathological significance of CD133 in lung cancer: a meta-analysis. Mol Clin Oncol. 2014;2:111–115.
   PubMedGoogle Scholar
• Tachezy M, Zander H, Wolters-Eisfeld G, et al. Activated leukocyte cell adhesion molecule (CD166): an “inert” cancer stem cell marker for non-small cell lung cancer? Stem Cells. 2014;32:1429–1436.
   PubMed Web of Science ®Google Scholar
• Zakaria N, Yusoff NM, Zakaria Z, et al. Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells. BMC Cancer. 2015;15:84.
   PubMed Web of Science ®Google Scholar
• Sullivan JP, Spinola M, Dodge M, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010;70:9937–9948.
   PubMed Web of Science ®Google Scholar
• Skirecki T, Hoser G, Kawiak J, et al. Flow cytometric analysis of CD133- and EpCAM-positive cells in the peripheral blood of patients with lung cancer. Arch Immunol Ther Exp (Warsz). 2014;62:67–75.
   PubMed Web of Science ®Google Scholar
• Yan X, Luo H, Zhou X, et al. Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines. Oncol Rep. 2013;30:2733–2740.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang Y, Ju X, et al. Clinicopathological significance of ALDH1A1 in lung, colorectal, and breast cancers: a meta-analysis. Biomark Med. 2015;9:777–790.
   PubMed Web of Science ®Google Scholar
• Xia P, Gou WF, Wang JJ, et al. Distinct radiosensitivity of lung carcinoma stem-like side population and main population cells. Cancer Biother Radiopharm. 2013;28:471–478.
   PubMed Web of Science ®Google Scholar
• Morrison BJ, Steel JC, Morris JC. Sphere culture of murine lung cancer cell lines are enriched with cancer initiating cells. Plos One. 2012;7:e49752.
   Google Scholar
• Salcido CD, Larochelle A, Taylor BJ, et al. Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer. 2010;102:1636–1644.
   PubMed Web of Science ®Google Scholar
• Togashi Y, Hayashi H, Terashima M, et al. Inhibition of beta-catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation. J Thorac Oncol. 2015;10:93–101.
   PubMed Web of Science ®Google Scholar
• Teng Y, Wang X, Wang Y, et al. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun. 2010;392:373–379.
   PubMed Web of Science ®Google Scholar
• Shapiro M, Akiri G, Chin C, et al. Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer. Ann Surg. 2013;257:548–554.
   PubMed Web of Science ®Google Scholar
• Espada J, Calvo MB, Diaz-Prado S, et al. Wnt signalling and cancer stem cells. Clin Translational Oncology: Off Publ Fed Spanish Oncol Societies Natl Cancer Inst Mexico. 2009;11:411–427.
   Google Scholar
• Zhang X, Lou Y, Wang H, et al. Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells. Med Oncol. 2015;32:95.
   PubMed Web of Science ®Google Scholar
• O’Connor ML, Xiang D, Shigdar S, et al. Cancer stem cells: a contentious hypothesis now moving forward. Cancer Letters. 2014;344:180–187.
   PubMed Web of Science ®Google Scholar
• Chen S, Guttridge DC, You Z, et al. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol. 2001;152:87–96.
   PubMed Web of Science ®Google Scholar
• Barr MP, Gray SG, Hoffmann AC, et al. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. Plos One. 2013;8(1):e54193.
   PubMed Web of Science ®Google Scholar
• Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res: Off J Am Assoc Cancer Res. 2010;16:3153–3162.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu Z, Zhang X, et al. Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells. Cancer Letters. 2013;336:231–239.
   PubMed Web of Science ®Google Scholar
• Lee SB, Gong Y-D, Park YI, et al. 2,3,6-Trisubstituted quinoxaline derivative, a small molecule inhibitor of the Wnt/beta-catenin signaling pathway, suppresses cell proliferation and enhances radiosensitivity in A549/Wnt2 cells. Biochem Biophys Res Commun. 2013;431:746–752.
   PubMed Web of Science ®Google Scholar
• Li X, Cai L, Liang M, et al. ING4 induces cell growth inhibition in human lung adenocarcinoma A549 cells by means of Wnt-1/beta-catenin signaling pathway. Anat Rec (Hoboken). 2008;291:593–600.
   PubMedGoogle Scholar
• Zhao J, Ma MZ, Ren H, et al. Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy. Clin Cancer Res: Off J Am Assoc Cancer Res. 2013;19:3567–3576.
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339–346.
   PubMed Web of Science ®Google Scholar
• Remon J, Moran T, Majem M, et al. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. Cancer Treat Rev. 2014;40:93–101.
   PubMed Web of Science ®Google Scholar
• Casas-Selves M, Kim J, Zhang Z, et al. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012;72:4154–4164.
   PubMed Web of Science ®Google Scholar
• Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008;105:2070–2075.
   PubMed Web of Science ®Google Scholar
• Fang X, Gu P, Zhou C, et al. beta-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells. Pulm Pharmacol Ther. 2014;28:41–48.
   PubMed Web of Science ®Google Scholar
• Botting GM, Rastogi I, Chhabra G, et al. Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in non-small cell lung cancer. Plos One. 2015;10:e0136155.
   Google Scholar
• Stewart EL, Tan SZ, Liu G, et al. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations – a review. Translational Lung Cancer Res. 2015;4:67–81.
   PubMed Web of Science ®Google Scholar
• Tibaldi C, D’Incecco A, Lagana A. MicroRNAs and targeted therapies in non-small cell lung cancer: minireview. Anticancer Agents Med Chem. 2015;15:694–700.
   PubMed Web of Science ®Google Scholar
• Song JL, Nigam P, Tektas SS, et al. microRNA regulation of Wnt signaling pathways in development and disease. Cell Signal. 2015;27:1380–1391.
   PubMed Web of Science ®Google Scholar
• Takahashi RU, Miyazaki H, Ochiya T. The role of microRNAs in the regulation of cancer stem cells. Front Genet. 2014;4:295.
   PubMed Web of Science ®Google Scholar
• Ghahhari NM, Babashah S. Interplay between microRNAs and WNT/beta-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur J Cancer. 2015;51:1638–1649.
   PubMed Web of Science ®Google Scholar
• Ling DJ, Chen ZS, Zhang YD, et al. MicroRNA-145 inhibits lung cancer cell metastasis. Mol Med Rep. 2015;11:3108–3114.
   PubMed Web of Science ®Google Scholar
• MacDonagh L, Gray SG, Finn SP, et al. The emerging role of microRNAs in resistance to lung cancer treatments. Cancer Treat Rev. 2015;41:160–169.
   PubMed Web of Science ®Google Scholar
• Tan M, Wu J, Cai Y. Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer. Biochem Biophys Res Commun. 2013;438:673–679.
   PubMed Web of Science ®Google Scholar
• Avasarala S, Van Scoyk M, Wang J, et al. hsa-miR29b, a critical downstream target of non-canonical Wnt signaling, plays an anti-proliferative role in non-small cell lung cancer cells via targeting MDM2 expression. Biol Open. 2013;2:675–685.
   PubMed Web of Science ®Google Scholar
• Wang J, Li Z, Ge Q, et al. Characterization of microRNA transcriptome in tumor, adjacent, and normal tissues of lung squamous cell carcinoma. J Thorac Cardiovasc Surg. 2015;149:1404–14 e4.
   PubMed Web of Science ®Google Scholar
• Mine M, Yamaguchi K, Sugiura T, et al. miR-203 inhibits frizzled-2 expression via CD82/KAI1 expression in human lung carcinoma cells. Plos One. 2015;10:e0131350.
   Web of Science ®Google Scholar
• Song Q, Xu Y, Yang C, et al. miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res. 2014;74:3031–3042.
   PubMed Web of Science ®Google Scholar
• Xi S, Xu H, Shan J, et al. Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J Clin Invest. 2013;123:1241–1261.
   PubMed Web of Science ®Google Scholar
• Wu D, Shi M, Fan XD. Mechanism of miR-21 via Wnt/beta-catenin signaling pathway in human A549 lung cancer cells and Lewis lung carcinoma in mice. Asian Pac J Trop Med. 2015;8:479–484.
   PubMedGoogle Scholar
• Xi S, Yang M, Tao Y, et al. Cigarette smoke induces C/EBP-beta-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells. Plos One. 2010;5:E148–E161.
   Web of Science ®Google Scholar
• Xu W, Ji J, Xu Y, et al. MicroRNA-191, by promoting the EMT and increasing CSC-like properties, is involved in neoplastic and metastatic properties of transformed human bronchial epithelial cells. Mol Carcinog. 2015;54(Suppl 1):E148–61.
   Google Scholar
• Zhou AD, Diao LT, Xu H, et al. beta-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/beta-catenin-signaling pathway. Oncogene. 2012;31:2968–2978.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xia H, Zhuang Z, et al. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. Cell Death Dis. 2014;5:e1227.
   Google Scholar
• Jang JS, Jeon HS, Sun Z, et al. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res: Off J Am Assoc Cancer Res. 2012;18:3658–3667.
   PubMed Web of Science ®Google Scholar
• Yan A, Yang C, Chen Z, et al. MiR-761 promotes progression and metastasis of non-small cell lung cancer by targeting ING4 and TIMP2. Cell Physiol Biochemistry: Int J Exp Cell Physiology, Biochemistry, Pharmacol. 2015;37:55–66.
   PubMed Web of Science ®Google Scholar
• Ho CS, Yap SH, Phuah NH, et al. MicroRNAs associated with tumour migration, invasion and angiogenic properties in A549 and SK-Lu1 human lung adenocarcinoma cells. Lung Cancer. 2014;83:154–162.
   PubMed Web of Science ®Google Scholar
• Gao W, Xu J, Liu L, et al. A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed Pharmacother. 2012;66:21–28.
   PubMed Web of Science ®Google Scholar
• Katoh M. Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. Front Cell Dev Biol. 2014;2:61.
   PubMed Web of Science ®Google Scholar
• Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of porcupine by LGK974. Proc Natl Acad Sci U S A. 2013;110:20224–20229.
   PubMed Web of Science ®Google Scholar
• Lee JS, Hur MW, Lee SK, et al. A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer. Plos One. 2012;7:e36520.
   Google Scholar
• Busch AM, Johnson KC, Stan RV, et al. Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer. 2013;13:211.
   PubMed Web of Science ®Google Scholar
• Bi X, Xia X, Mou T, et al. Anti-tumor activity of three ginsenoside derivatives in lung cancer is associated with Wnt/beta-catenin signaling inhibition. Eur J Pharmacol. 2014;742:145–152.
   PubMed Web of Science ®Google Scholar
• Bol GM, Vesuna F, Xie M, et al. Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO Mol Med. 2015;7:648–669.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Sperl B, Ullrich A, et al. Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status. Oncotarget. 2014;5:12877–12890.
   PubMed Web of Science ®Google Scholar
• Arafat K, Iratni R, Takahashi T, et al. Inhibitory effects of salinomycin on cell survival, colony growth, migration, and invasion of human non-small cell lung cancer A549 and LNM35: involvement of NAG-1. Plos One. 2013;8:e6691.
   Web of Science ®Google Scholar
• Wang Y. Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. Med Chem (Los Angeles). 2011;7:106–111.
   Web of Science ®Google Scholar
• Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461:614–620.
   PubMed Web of Science ®Google Scholar
• Moheimani F, Roth HM, Cross J, et al. Disruption of beta-Catenin/CBP signaling inhibits human airway epithelial-mesenchymal transition and repair. Int J Biochem Cell Biol. 2015;68:59–69.
   PubMed Web of Science ®Google Scholar
• Yao H, Ashihara E, Strovel JW, et al. AV-65, a novel Wnt/beta-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. Blood Cancer Journal. 2011;1:e43.
   Google Scholar
• Lepourcelet M, Chen YN, France DS, et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004;5:91–102.
   PubMed Web of Science ®Google Scholar
• Handeli S, Simon JA. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther. 2008;7:521–529.
   PubMed Web of Science ®Google Scholar
• Wu K, Ning Z, Zeng J, et al. Silibinin inhibits beta-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cell Signal. 2013;25:2625–2633.
   PubMed Web of Science ®Google Scholar
• Song JM, Qian X, Molla K, et al. Combinations of indole-3-carbinol and silibinin suppress inflammation-driven mouse lung tumorigenesis by modulating critical cell cycle regulators. Carcinogenesis. 2015;36:666–675.
   PubMed Web of Science ®Google Scholar
• Hitt E. Wnt signaling inhibition: will decades of effort be fruitful at last? OncLive 2013. [cited November 14, 2013]. http://www.onclive.com/publications/oncology-live/2012/december-2012/Wnt-Signaling-Inhibition-Will-Decades-of-Effort-Be-Fruitful-at-Last
   Google Scholar
• Fukukawa C, Hanaoka H, Nagayama S, et al. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 2008;99:432–440.
   PubMed Web of Science ®Google Scholar
• OTSA101. First in man study investigating the biodistribution, the safety and optimal recommended dose of a new radiolabelled monoclonal antibody targeting frizzled homolog 10 (SYNFRIZZ). Clinicaltrials.gov. 2015;2015:NCT01469975.
   Google Scholar
• Gurney A, Axelrod F, Bond CJ, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012;109:11717–11722.
   PubMed Web of Science ®Google Scholar
• Tennis MA, Van Scoyk M, Heasley LE, et al. Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia. 2010;12:244–253.
   PubMed Web of Science ®Google Scholar
• Gray JE, Infante JR, Brail LH, et al. A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Invest New Drugs. 2015;33:1187–1196.
   PubMed Web of Science ®Google Scholar
• Liu YL, Yang HP, Zhou XD, et al. The hypomethylation agent bisdemethoxycurcumin acts on the WIF-1 promoter, inhibits the canonical Wnt pathway and induces apoptosis in human non-small-cell lung cancer. Curr Cancer Drug Targets. 2011;11:1098–1110.
   PubMed Web of Science ®Google Scholar
• Xu JH, Yang HP, Zhou XD, et al. Role of Wnt inhibitory factor-1 in inhibition of bisdemethoxycurcumin mediated epithelial-to-mesenchymal transition in highly metastatic lung cancer 95D cells. Chin Med J. 2015;128:1376–1383.
   PubMed Web of Science ®Google Scholar
• Gao Z, Xu Z, Hung MS, et al. Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells. Oncol Rep. 2009;22:1479–1484.
   PubMed Web of Science ®Google Scholar
• Nakayama S, Sng N, Carretero J, et al. beta-catenin contributes to lung tumor development induced by EGFR mutations. Cancer Res. 2014;74:5891–5902.
   PubMed Web of Science ®Google Scholar
• Waaler J, Machon O, Tumova L, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012;72:2822–2832.
   PubMed Web of Science ®Google Scholar
• Lau T, Chan E, Callow M, et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 2013;73:3132–3144.
   PubMed Web of Science ®Google Scholar
• Kim YM, Ma H, Oehler VG, et al. The gamma catenin/CBP complex maintains survivin transcription in beta-catenin deficient/depleted cancer cells. Curr Cancer Drug Targets. 2011;11:213–225.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wei C, Xi Z. Curcumin suppresses proliferation and invasion in non-small cell lung cancer by modulation of MTA1-mediated Wnt/beta-catenin pathway. In Vitro Cell Dev Biol Anim. 2014;50:840–850.
   PubMed Web of Science ®Google Scholar
• Corominas-Faja B, Oliveras-Ferraros C, Cuyas E, et al. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle. 2013;12:3390–3404.
   PubMed Web of Science ®Google Scholar
• Son Y, Lee HJ, Rho JK, et al. The ameliorative effect of silibinin against radiation-induced lung injury: protection of normal tissue without decreasing therapeutic efficacy in lung cancer. BMC Pulm Med. 2015;15:68.
   PubMed Web of Science ®Google Scholar
• Lu W, Lin C, King TD, et al. Silibinin inhibits Wnt/beta-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal. 2012;24:2291–2296.
   PubMed Web of Science ®Google Scholar
• Iftikhar H, Rashid S. Molecular docking studies of flavonoids for their inhibition pattern against beta-catenin and pharmacophore model generation from experimentally known flavonoids to fabricate more potent inhibitors for Wnt signaling pathway. Pharmacogn Mag. 2014;10:S264–71.
   Google Scholar
• Lenz HJ, Kahn M. Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci. 2014;105:1087–1092.
   PubMed Web of Science ®Google Scholar
• Nagaraj AB, Joseph P, Kovalenko O, et al. Critical role of Wnt/beta-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget. 2015;6:23720–23734.
   PubMed Web of Science ®Google Scholar
• Scarpa ES, Ninfali P. Phytochemicals as innovative therapeutic tools against cancer stem cells. Int J Mol Sci. 2015;16:15727–15742.
   PubMed Web of Science ®Google Scholar
• Cai SX, Liu AR, Chen S, et al. Activation of Wnt/beta-catenin signalling promotes mesenchymal stem cells to repair injured alveolar epithelium induced by lipopolysaccharide in mice. Stem Cell Res Ther. 2015;6:65.
   PubMed Web of Science ®Google Scholar
• Kuncewitch M, Yang WL, Jacob A, et al. Stimulation of Wnt/beta-catenin signaling pathway with Wnt agonist reduces organ injury after hemorrhagic shock. J Trauma Acute Care Surg. 2015;78:793–800.
   PubMed Web of Science ®Google Scholar
• Hommura F, Furuuchi K, Yamazaki K, et al. Increased expression of beta-catenin predicts better prognosis in nonsmall cell lung carcinomas. Cancer. 2002;94:752–758.
   PubMed Web of Science ®Google Scholar